![137766-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137766-Thumbnail%20Image.png?versionId=goNsuWx6CXAVwn57Z2Os.SjlTrsf.tib&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T203459Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=e383ffd573e9cde7d6356dabfc30b0abcca4720ed2922f72c419fc8b7d0c42fe&itok=i2ooAimc)
![171757-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2022-12/171757-Thumbnail%20Image.png?versionId=QsrhPbqnn9XDDkWMrbaSUct0hAc8yGNX&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T030226Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=9c803f6935366d80435cf42e7d7010b37fbae9678c98439420cac73e2955baa4&itok=65sH12W_)
![189275-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2023-08/189275-Thumbnail%20Image.png?versionId=AxBlb9._duNBvtGiE9iOLyV3UmkhmRyK&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T133632Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=e3178a2f463aa7a850fc0b0315583c8b5fa2dae957f82291662225654f491a75&itok=y01xFIr_)
![190923-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2023-12/190923-Thumbnail%20Image.png?versionId=N7Fs4QAycYfFeEi0lPMqaaOL_WvFq6GO&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T183434Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=b284e03794b9cf396aa4645f465a897e14f7421f554bcd391bafaa7d99a8e066&itok=zBFqiZPt)
![190831-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2023-12/190831-Thumbnail%20Image.png?versionId=p_5dr_8H_BAtKnKYHeQIqK2jeTSSLDIz&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T183434Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=79abe8160eaaaaa7e18fe201394a3d55ccf367317f85740bd65a91169da1af33&itok=06rrk9vt)
![193690-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2024-05/193690-Thumbnail%20Image.png?versionId=a6txB5_JZ6CuaRUgaI_MhoqcVA0D0Msk&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T073552Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=dfacba3ec4147770c8fc2a55ecd12e80dff257ad60b76be65bd473a9542cd2f8&itok=IG_Dz2-U)
![161062-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-11/161062-Thumbnail%20Image.png?versionId=mwvvn_RDQdDA3YdyuzlCincPJQFisirI&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T183434Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=f52b697ae6c39ad25c5df7e55167c479f70fa078c21029c08e6e95c18fca3906&itok=s6QrumjF)
Early detection of disease is essential for alleviating disease burden, increasing success rate and decreasing mortality rate especially for cancer. To improve disease diagnostics, many candidate biomarkers have been suggested using molecular biology or image analysis techniques over the past decade. The receiver operating characteristics (ROC) curve is a standard technique to evaluate a diagnostic accuracy of biomarkers, but it has some limitations especially for heterogeneous diseases. As an alternative of the ROC curve analysis, we suggest a jittered dot plot (JDP) and JDP-based evaluation measures, above mean difference (AMD) and averaged above mean difference (AAMD). We demonstrate how JDP and AMD or AAMD together better evaluate biomarkers than the standard ROC curve. We analyze real and heterogeneous basal-like breast cancer data.
Throughout the long history of virus-host co-evolution, viruses have developed delicate strategies to facilitate their invasion and replication of their genome, while silencing the host immune responses through various mechanisms. The systematic characterization of viral protein-host interactions would yield invaluable information in the understanding of viral invasion/evasion, diagnosis and therapeutic treatment of a viral infection, and mechanisms of host biology. With more than 2,000 viral genomes sequenced, only a small percent of them are well investigated. The access of these viral open reading frames (ORFs) in a flexible cloning format would greatly facilitate both in vitro and in vivo virus-host interaction studies. However, the overall progress of viral ORF cloning has been slow. To facilitate viral studies, we are releasing the initiation of our panviral proteome collection of 2,035 ORF clones from 830 viral genes in the Gateway® recombinational cloning system. Here, we demonstrate several uses of our viral collection including highly efficient production of viral proteins using human cell-free expression system in vitro, global identification of host targets for rubella virus using Nucleic Acid Programmable Protein Arrays (NAPPA) containing 10,000 unique human proteins, and detection of host serological responses using micro-fluidic multiplexed immunoassays. The studies presented here begin to elucidate host-viral protein interactions with our systemic utilization of viral ORFs, high-throughput cloning, and proteomic technologies. These valuable plasmid resources will be available to the research community to enable continued viral functional studies.
![129310-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/129310-Thumbnail%20Image.png?versionId=mihWnRH0AaV.YGXoZ0Zo3yLdMSfP_Zjc&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T170022Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=8a8a8413e8d049e51eaafb98da3451cbdbdc1886d2498b6c6a331a08d0822414&itok=e5JUZK_m)
Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22% at >93% specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60% (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3% at 98.3% specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.